Novel genetically engineered mouse models for clear cell renal cell carcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 05 2023
22 05 2023
Historique:
received:
02
09
2022
accepted:
12
05
2023
medline:
24
5
2023
pubmed:
23
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Genetically engineered mouse models (GEMMs) are important immunocompetent models for research into the roles of individual genes in cancer and the development of novel therapies. Here we use inducible CRISPR-Cas9 systems to develop two GEMMs which aim to model the extensive chromosome p3 deletion frequently observed in clear cell renal cell carcinoma (ccRCC). We cloned paired guide RNAs targeting early exons of Bap1, Pbrm1, and Setd2 in a construct containing a Cas9
Identifiants
pubmed: 37217526
doi: 10.1038/s41598-023-35106-7
pii: 10.1038/s41598-023-35106-7
pmc: PMC10203127
doi:
Substances chimiques
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
8246Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK113088
Pays : United States
Organisme : NIH HHS
ID : S10 OD023652
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16538-43
pubmed: 25359211
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
Cell. 2016 Dec 15;167(7):1883-1896.e15
pubmed: 27984734
Nat Commun. 2020 Aug 17;11(1):4111
pubmed: 32807776
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Cell Rep. 2017 Mar 21;18(12):2893-2906
pubmed: 28329682
Nat Biotechnol. 2016 Jul 12;34(7):695-7
pubmed: 27404874
Nat Commun. 2017 Jun 08;8:15770
pubmed: 28593993
N Engl J Med. 2019 Jun 27;380(26):2582
pubmed: 31242371
Cancer Res. 2011 Nov 1;71(21):6848-56
pubmed: 21908555
Cancer Res. 2006 Mar 1;66(5):2576-83
pubmed: 16510575
Mol Cell Proteomics. 2019 Jul;18(7):1320-1329
pubmed: 30992312
J Immunol. 2016 Jul 1;197(1):326-36
pubmed: 27233962
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
pubmed: 9636188
Front Oncol. 2021 Dec 14;11:783856
pubmed: 34970493
Nat Med. 2018 Jul;24(7):939-946
pubmed: 29892062
Genesis. 2006 Jan;44(1):23-8
pubmed: 16400644
Eur Urol. 2017 Mar;71(3):405-414
pubmed: 27751729
Sci Rep. 2014 Sep 19;4:6420
pubmed: 25236476
Sci Rep. 2020 Oct 19;10(1):17642
pubmed: 33077781
Mol Cancer Res. 2015 May;13(5):870-8
pubmed: 25715653
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Nat Methods. 2008 Feb;5(2):171-3
pubmed: 18204457
Nat Med. 2017 Jul;23(7):869-877
pubmed: 28553932
Science. 1998 Nov 20;282(5393):1497-501
pubmed: 9822382
Nephron Exp Nephrol. 2007;106(1):e11-20
pubmed: 17356303
Cell. 2018 Apr 19;173(3):595-610.e11
pubmed: 29656894
Genome Res. 2014 May;24(5):869-84
pubmed: 24515121
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Annu Rev Immunol. 2011;29:235-71
pubmed: 21219185
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1931-6
pubmed: 12574499
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1027-1032
pubmed: 28082722
Cell. 2018 Apr 19;173(3):581-594.e12
pubmed: 29656895
Cell. 2011 Apr 1;145(1):145-58
pubmed: 21458673
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Nat Med. 2018 Jul;24(7):927-930
pubmed: 29892067
N Engl J Med. 2021 Aug 19;385(8):683-694
pubmed: 34407342
Cell. 2014 Oct 9;159(2):440-55
pubmed: 25263330
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):301-13
pubmed: 14734483
Cell. 2018 Apr 19;173(3):611-623.e17
pubmed: 29656891
J Am Soc Nephrol. 2004 Jan;15(1):112-25
pubmed: 14694163
J Clin Invest. 2002 Aug;110(3):341-50
pubmed: 12163453
Nat Biotechnol. 2015 Apr;33(4):390-394
pubmed: 25690852
J Immunol. 2015 Jan 15;194(2):709-18
pubmed: 25505291
Nat Genet. 2012 Jun 10;44(7):751-9
pubmed: 22683710
Cell. 2013 Sep 12;154(6):1380-9
pubmed: 23992846